Joint Pain Injections Market 2020-2028 Covid-19 Updates With Key Players Anika Therapeutics, Inc., Bioventus – Owned

Joint Pain Injections Market Scenario 2020-2028:

This detailed market study covers Joint Pain Injections Market growth potentials which can assist the stake holders to understand key trends and prospects in Joint Pain Injections market identifying the growth opportunities and competitive scenarios. The report also focuses on data from different primary and secondary sources, and is analyzed using various tools. It helps to gain insights into the markets growth potential, which can help investors identify scope and opportunities. The analysis also provides details of each segment in the global Joint Pain Injections market

Sample Copy of This Report: https://www.quincemarketinsights.com/request-sample-65228?utm_source=PF/komal

Company profiled in this report based on Business overview, Financial data, Product landscape, Strategic outlook & SWOT analysis: Anika Therapeutics, Inc., Bioventus, Ferring Pharmaceuticals Inc., Sanofi, Zimmer Biomet.

According to the report, the Joint Pain Injections market report points out national and global business prospects and competitive conditions for Joint Pain Injections. Market size estimation and forecasts were given based on a detailed research methodology tailored to the conditions of the demand for Joint Pain Injections. The Joint Pain Injections market has been Segmented By Type of Injection (Steroid Joint Injections, Hyaluronic Acid Injections, Platelet-rich Plasma (PRP) Injections, Placental Tissue Matrix (PTM) Injections), By Application (Shoulder & Elbow, Knee & Ankle, Spinal Joints, Hip Joint). Historical background for the demand of Joint Pain Injections has been studied according to organic and inorganic innovations in order to provide accurate estimates of the market size. Primary factors influencing the growth of the demand Joint Pain Injections have also been established with potential gravity.

Joint Pain Injections

Regional segmentation and analysis to understand growth patterns: The market has been segmented in major regions to understand the global development and demand patterns of this market. By region, the Joint Pain Injections market has been segmented in North America, Europe, Asia Pacific, Middle East & Africa, and South America. The North America and Western Europe regions are estimated to register a stable demand during the forecast period with market recovery from recent slowdowns.

North America region includes the US, Canada, and Mexico. The US is estimated to dominate this market with a sizeable share followed by Canada, and Mexico. The industrial sector is a major contributor to the US and Canada economies overall. Hence, the supply of advanced materials in production activities is critical to the overall growth of industries in this region.

Get ToC for the overview of the premium report @ https://www.quincemarketinsights.com/request-toc-65228?utm_source=PF/komal

Europe region is dominated by Germany, the UK, France, Italy, and Spain. These countries also have a strong influence on the industrial sector resulting in sizeable demand for Joint Pain Injections market. Asia Pacific is estimated to register the highest CAGR by region during the forecast period. The presence of some of the high growth economies such as China and India is expected to propel the demand in this region. Besides, this region has witnessed strategic investments by major companies to increase their market presence. The Middle East and Eastern Europe are estimated to be other key regions for the Joint Pain Injections market with a strong market potential during the forecast period. Rest of the World consisting of South America and Africa are estimated to be emerging markets during the forecast period.

This report provides: 1) An overview of the global market for Joint Pain Injections market and related technologies. 2) Analysis of global market trends, yearly estimates and annual growth rate projections for compounds (CAGRs). 3) Identification of new market opportunities and targeted consumer marketing strategies for global Joint Pain Injections market. 4) Analysis of R&D and demand for new technologies and new applications 5) Extensive company profiles of key players in industry.

The researchers have studied the market in depth and have developed important segments such as product type, application and region. Each and every segment and its sub-segments are analyzed based on their market share, growth prospects and CAGR. Each market segment offers in-depth, both qualitative and quantitative information on market outlook.

If Make an Enquiry for purchasing this Report @ https://www.quincemarketinsights.com/enquiry-before-buying/enquiry-before-buying-65228?utm_source=PF/komal

Objectives of this report: To estimate market size for Joint Pain Injections market on regional and global basis. To identify major segments in Joint Pain Injections market and evaluate their market shares and demand. To provide a competitive scenario for the Joint Pain Injections market with major developments observed by key companies in the historic years. To evaluate key factors governing the dynamics of Joint Pain Injections market with their potential gravity during the forecast period.

About US: QMI has the most comprehensive collection of market research products and services available on the web. We deliver reports from virtually all major publications and refresh our list regularly to provide you with immediate online access to the worlds most extensive and up-to-date archive of professional insights into global markets, companies, goods, and patterns.

Contact US: Quince Market Insights

Ajay D. (Knowledge Partner)

Office No- A109

Pune, Maharashtra 411028

Phone: APAC +91 706 672 4848 / US +1 208 405 2835 / UK +44 1444 39 0986

Email: [emailprotected]

Web: https://www.quincemarketinsights.com

Read the original here:
Joint Pain Injections Market 2020-2028 Covid-19 Updates With Key Players Anika Therapeutics, Inc., Bioventus - Owned

Another Nice Thing We Can’t Have in 2020: Shohei Ohtani’s Pitching – FanGraphs

The list of things that havent gone according to plan in 2020 is long enough to reach to the moon and back, and to that, we can add the return of Shohei Ohtani to competitive pitching. After more than a year spent recovering from Tommy John surgery, the 26-year-old wonders reacquaintance with the mound was hotly anticipated, but after two brief and miserable outings, hes injured, and Angels manager Joe Maddon said on Tuesday that he doesnt expect to see Ohtani pitch again this year.

On Sunday, Ohtani made his second start of the season, and it began with promise, as he retired the top of the Astros lineup George Springer, Jose Altuve, and Alex Bregman in order on a total of eight pitches. He topped 95 mph a few times with his four-seamer, struck out Springer swinging at a splitter, and induced Altuve to pop up a bunt foul. Heres the Springer strikeout:

Things were looking up, particularly given that in his July 26 start against the As, Ohtani failed to retire any of the six hitters he faced, yielding three hits, three walks, and five runs. Though he dialed his fastball as high as 97.1 mph in the second inning on Sunday, he labored and grew visibly frustrated while walking the bases loaded on 26 pitches. He went to two strikes on six consecutive hitters, squandering 0-2 counts twice before striking out Kyle Tucker and Jack Mayfield. By the time he walked both Dustin Garneau and Springer, he had thrown 42 pitches in the inning a ridiculously high number in any context, let alone one for a pitcher in his second start back from surgery. His three fastballs to Springer in the second inning failed to break 90 mph; belatedly, Maddon gave him the hook, bringing in Jose Rodriguez, who retired Altuve via a groundout.

I thought it was fatigue, from where I was standing, said Maddon of Ohtanis rough second inning. We were trying to get him out there as quickly as we could at that point. There was also the chance that he could get through it, and then I wasnt certain if hed be able to continue or not. It was one of those cusp situations. I thought he was just out of his delivery at that point.

Once removed, however, Ohtani complained of discomfort in his forearm, prompting an MRI exam. He was diagnosed with a Grade 1-2 strain of his flexor pronator mass, which helps in part to explain why his average fastball velocity has been so far removed from 2018 (93.8 mph vs. 97.4, via Pitch Info). Hell be shut down from throwing for four to six weeks, which likely would not leave him enough time to build up to game activity on the mound. He will remain available to serve as a designated hitter, though for the moment hes considered day-to-day, like the rest of us.

Im not anticipating him pitching at all this year, Maddon told reporters on Tuesday. In whatever kind of throwing program, itll be very conservative. I dont have any projection on that other than hes not going to pitch this year.

This is a heartbreaker. Ohtani dazzled the baseball world with a nine-start run in early 2018, before a blister and then elbow soreness sidelined him in early June. Diagnosed with a Grade 2 sprain of his ulnar collateral ligament, he underwent both both platelet-rich plasma and stem-cell injections, but lasted just 2.1 innings in his return to the mound on September 2. Soon after that, doctors recommended that he undergo Tommy John surgery, which he did in October 2018. He returned to the majors on May 7 of last season, and spent the remainder of the year splitting his time between rehabbing his throwing arm and serving as a DH, but in September it was discovered that he needed surgery on his left knee to repair a bipartite patella, a congenital issue that had been aggravating him throughout the season. In his injury-bookended campaign, Ohtani hit .286/.343/.505 with 18 homers and 12 steals in 425 PA before being shut down, a very good performance but a step down from his .285/.361/.564 (151 wRC+) as a rookie.

The knee surgery delayed Ohtanis post-Tommy John rehab program, but he finally completed it in December, after which he was shut down until spring training. The plan as of February was that he would return to the mound in mid-May, pitching once a week, and that he would have an innings limit. The coronavirus pandemic delayed those plans but he started the Angels third game of the season, and there was plenty of optimism that he could help the teams quest to reach the postseason for the first time since 2014.

Now, if hes going to do it, hell have to do so as the primary DH. So far, things havent gone that well for Ohtani on that side of the ball, either; hes hitting .148/.179/.407 with two homers, one walk, and nine strikeouts in 28 PA. Despite those ugly numbers, hes actually making good contact, with an average exit velocity of 91.7 mph, an xwOBA of .382, and an xSLG of .642.

The Angels rotation will be the poorer without Ohtani, though the other five pitchers who have started (Dylan Bundy, Andrew Heaney, Griffin Canning, Matt Andriese, and Patrick Sandoval, the last two of whom have taken just one start apiece) have combined for a 3.45 ERA and 3.00 FIP thus far. The return of Julio Teheran, who arrived in camp late after testing positive for COVID-19, will help compensate for Ohtanis loss; hell make his Angels debut on Wednesday, starting against the Mariners, but even so, the rotation ranks just 19th in the majors in our projection-driven Depth Charts, suggesting that the units current overperformance which has still only led to a 4-7 record thus far may be fleeting.

The Angels still view Ohtani as a legitimate two-way player, but should they? His total body of work on major league mounds now amounts to 12 outings spread over three seasons, with three appearances totaling four innings since June 6, 2018. Recall that he also made just five starts for the Nippon Ham Fighters in 2017, his final year in NPB, due to a right ankle injury that required surgery. In other words, hes thrown just 78.2 competitive innings over four seasons, with the previous three ending with an injury that required surgery, and hell head into another offseason with health questions. Thats a lot of work and a lot of rehab with only a minimal payoff, and it has come with roster issues that the Angels have had to work around days off before and after his starts, and extra rest between starts, necessitating some rotation juggling. With a healthy Ohtani playing every day in an outfield alongside Mike Trout and Jo Adell (who made his major league debut on Tuesday night, going 1-for-4 with an infield single that showed off his elite speed), that unit might be the best in baseball and the cornerstone of a contender.

On the other hand, Ohtani has shown that he has high-quality stuff on the mound, this years struggles notwithstanding. He pitched to a 3.31 ERA and 3.57 FIP with a 29.1% strikeout rate in 2018, and Sundays first inning suggested that he can still get good hitters out even if hes not dialing it up to 100 mph. A player who can put up All-Star caliber rate stats as both a pitcher and a hitter is a once-in-a-century talent; Ohtanis high-level performance as both a pitcher and hitter has only early Babe Ruths 1918 and 19 seasons as a precedent. To give up on that simply so that Maddon has an everyday DH or outfielder to write into the lineup feels like using a Van Gogh painting as a TV tray.

Maddon told reporters he still believes Ohtani can be a two-way player. We just got to get past the arm maladies and figure that out, he said. Hes such a high-end arm and, of course, what he can do in the batters box. It might get to the point where he may choose to want to do one thing over the other and just express that to us.

So far as anybody knows, thats not the case yet, and in a normal six-month season, Ohtanis forearm strain would be viewed as a setback, not a crossroads. He wont be able to help the Angels as a pitcher during this brief, weird season, but thats not enough of a reason to surrender the possibility that he could return to dazzling the baseball world with his unique combination of talents.

We hoped you liked reading Another Nice Thing We Cant Have in 2020: Shohei Ohtanis Pitching by Jay Jaffe!

Please support FanGraphs by becoming a member. We publish thousands of articles a year, host multiple podcasts, and have an ever growing database of baseball stats.

FanGraphs does not have a paywall. With your membership, we can continue to offer the content you've come to rely on and add to our unique baseball coverage.

Support FanGraphs

Original post:
Another Nice Thing We Can't Have in 2020: Shohei Ohtani's Pitching - FanGraphs

Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market: Extensive Analysis of Key Segments of the Industry and Emerging Growth Factors…

In this report, the global Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies market is valued at USD XX million in 2019 and is projected to reach USD XX million by the end of 2025, growing at a CAGR of XX% during the period 2019 to 2025.

For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2019 to 2025.

The Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies market report firstly introduced the basics: definitions, classifications, applications and market overview; product specifications; manufacturing processes; cost structures, raw materials and so on. Then it analyzed the worlds main region market conditions, including the product price, profit, capacity, production, supply, demand and market growth rate and forecast etc. In the end, the Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies market report introduced new project SWOT analysis, investment feasibility analysis, and investment return analysis.

Get PDF Sample Copy of this Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart) @ https://www.marketresearchhub.com/enquiry.php?type=S&repid=2601860&source=atm

The key players covered in this study Orange County Hair Restoration Center Hair Sciences Center of Colorado Anderson Center for Hair Evolution Hair Loss Institute Savola Aesthetic Dermatology Center Virginia Surgical Center Hair Transplant Institute of Miami Colorado Surgical Center & Hair Institute

Market segment by Type, the product can be split into Platelet Rich Plasma Injections Stem Cell Therapy Market segment by Application, split into Dermatology Clinics Hospitals

Market segment by Regions/Countries, this report covers North America Europe China Japan Southeast Asia India Central & South America

The study objectives of this report are: To analyze global Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies status, future forecast, growth opportunity, key market and key players. To present the Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America. To strategically profile the key players and comprehensively analyze their development plan and strategies. To define, describe and forecast the market by type, market and key regions.

In this study, the years considered to estimate the market size of Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies are as follows: History Year: 2015-2019 Base Year: 2019 Estimated Year: 2020 Forecast Year 2020 to 2026 For the data information by region, company, type and application, 2019 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Do You Have Any Query Or Specific Requirement? Ask to Our Industry [emailprotected] https://www.marketresearchhub.com/enquiry.php?type=E&repid=2601860&source=atm

The study objectives of Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market Report are:

To analyze and research the Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies market status and future forecast in United States, European Union and China, involving sales, value (revenue), growth rate (CAGR), market share, historical and forecast.

To present the Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies manufacturers, presenting the sales, revenue, market share, and recent development for key players.

To split the breakdown data by regions, type, companies and applications

To analyze the global and key regions Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies market potential and advantage, opportunity and challenge, restraints and risks.

To identify significant trends, drivers, influence factors in global and regions

To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the keyword market.

You can Buy This Report from Here @ https://www.marketresearchhub.com/checkout?rep_id=2601860&licType=S&source=atm

See the article here:
Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market: Extensive Analysis of Key Segments of the Industry and Emerging Growth Factors...

PRP Platelet-Rich Plasma | Florida Sports and Family …

Recent studies and experiments have shown that the human body has the natural ability to heal itself. Therefore, a technique known as PRP Platelet-Rich Plasma is introduced to the world. In this technique, a regenerative liquid is injected into the patient that will enhance and amplify the natural healing ability of the body.

To know more, first, lets break down the confusion between plasma and platelets.

Both plasma and platelets are vital for any healing process in the body.

As mentioned before, PRP Platelet-Rich Plasma is injected into the patients body where it is mixed with the existing plasma and move into the whole body. In this method, the injections contain the contraception of ones own platelets to treat musculoskeletal problems such as muscle sprain, joints pain, a dislocated shoulder, or anything, etc. With this treatment, patients have recovered from injured tendons, ligaments, muscles and joints.

The PRP Platelet-Rich Plasma injections are prepared by taking out the patients blood in a tube. Then it is run through the centrifuge to concentrate the platelets count. The doctors can take out more blood if needed depending upon the treatment plan, but it wouldnt be much. Now the PRP Platelet-Rich Plasma is ready to use. It is now injected into the part that is diseased or needs healing. To locate that part of the body, usually, ultrasound imaging is used. Once a doctor is injecting this, the healing process will stimulate and soon the patient will be fully recovered.

People who are looking to get fit through natural remedies have known to be a user of this technique. It improves function and reduces the pain in the affected areas of the body. One of the biggest advantages of using this technique is that you wont have to rely on painkiller medicines. As for the side effects, usually, there are none because the body is reacting to its own plasma and platelets.

Florida Family Sports and Health Center provides medical care to everyone through their range of services. It was founded by Doctor Joseph Torres in 1995. This health center covers sports medicine along with the other fields of medicine. Here all the doctors are certified and provide optimum health and wellness advice. The doctors here wont shy away from trying new methods and remedies to treat their patients. This new technique of PRP Platelet-Rich Plasma is a recent addition in the health center that will be used to cure more patients.

See the original post here:
PRP Platelet-Rich Plasma | Florida Sports and Family ...

Rockies vs. Athletics – Game Recap – July 28, 2020 – ESPN

OAKLAND, Calif. -- Sam Hilliard homered for the first time this season, Antonio Senzatela pitched out of an early jam on his way to a rare road win, and the Colorado Rockies beat the Oakland Athletics 8-3 Tuesday night.

Charlie Blackmon had two hits, David Dahl drove in a pair of runs and Nolan Arenado made up for an uncharacteristic fielding error with a single and sacrifice fly to help the Rockies to their third straight win following an opening day loss to Texas.

"We've got a good pitching staff always and this year we've been doing good," Senzatela said. "We were just working for that in the offseason, even through the quarantine. I think we deserve this."

Hilliard was hitless going into the day before doubling off A's starter Daniel Mengden in the second and then homering in the fourth. Hilliard, who homered in his major league debut last August, laced a 2-2 pitch into the right-field stands after Raimel Tapia singled.

"Sam's blast, the breaking ball in the seats was a great swing," Rockies manager Bud Black said. "I like the double the other way. We saw Sam do that a number of times last year, take pitches away from him, hit them to left field. The home run gave us a big lift."

Senzatela worked himself into an early jam but got Oakland slugger Khris Davis to pop out with the bases loaded in the first on the way to his first win on the road since July 5, 2019. The right-hander had dropped five straight away from home since then.

Senzatela (1-0) allowed two runs (one earned) and six hits in five innings. He walked three and struck out three.

"I threw too many pitches in the first inning but I just put on myself, `I need to make it through five to give the team a chance to win,' and I did it," Senzatela said.

Tyler Kinley, Daniel Bard and Carlos Estevez combined to two-hit the A's over the final four innings.

Ramon Laureano had two hits and Mark Canha added a sacrifice fly for the A's, who were attempting to go 4-1 for the first time since 2010.

Oakland manager Bob Melvin had been hopeful of resting his taxed bullpen but didn't get the chance after Mengden (0-1) lasted four innings and gave up three runs on five hits.

"Strike one can be a problem for him sometimes," Melvin said. "He tries to be a little too fine at times. It's getting the pitch count down and trying to get the other team to put the ball in play earlier in the count."

The Rockies tacked on a pair in the fifth with four consecutive one-out hits and a sacrifice fly off A's reliever Jordan Weems in his major league debut. They scored three more in the eighth.

MILESTONE, BUT NO HITS

Davis moved into second place in games played by A's designated hitters but continued to struggle at the plate. He struck out twice, popped up and hit into a double play in four at-bats, dropping the Oakland slugger to 0 for 15 this season.

"I've said all along that leashes can be a little bit shorter when you struggle in 60 games," Melvin said. "It's like being in August right now. Some of the guys who have track records deserve a little bit of a longer leash. He's been really good for us over the years."

The game marked the 356th for Davis as the A's DH, moving him past Mitchell Page on the franchise list. Davis will have to wait until next season to break Dave Kingman's mark of 428.

TRAINER'S ROOM

Athletics: Mengden pitched in a game for the first time since undergoing elbow surgery in February. He was moved into the rotation as left-hander A.J. Puk deals with a strained throwing shoulder that landed him on the injured list to start the season and required cortisone and platelet-rich plasma injections. . T.J. McFarland, Jake Diekman and Yusmeiro Petit, all of whom pitched three times in Oakland's first four games, were rested.

UP NEXT

The two-game series ends Wednesday afternoon when Oakland's Frankie Montas (0-0, 2.25 ERA) makes his second start of the season against Colorado's German Marquez (0-1, 1.59) in a matchup of right-handers. Marquez's loss on opening day was his first in 16 interleague starts.

---

More AP MLB: https://apnews.com/MLB and https://twitter.com/AP-Sports

Read more:
Rockies vs. Athletics - Game Recap - July 28, 2020 - ESPN

Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market 2020 COVID-19 Impact on Industry Size, Share, Company Profiles, Emerging…

Global Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market 2020 Industry Research Report is an inside-out and expert examination on the flow condition of the Global Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies industry. In addition to that, this latest investigative report sorts the global Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies market by end client, type, area, and top players/brands. This report further elaborates various factors affecting the market drivers and development. Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies market also puts forward insights into market size, crucial markers, review, as well as the most recent net edge, income, types, patterns, along with provincial figure and examination.

Get a Sample PDF of report at https://www.researchreportsworld.com/enquiry/request-sample/15618454

The objective of the study is to define market sizes of different segments and countries in previous years and to forecast the values to the next Five years. The report is designed to incorporate both qualify qualitative and quantitative aspects of the industry with respect to each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as drivers and restraining factors which will define the future growth of the Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies market.

To Understand How COVID-19 Impact is Covered in This Report. Get Sample copy of the report at https://www.researchreportsworld.com/enquiry/request-covid19/15618454

The research covers the current Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies market size of the market and its growth rates based on 6-year records with company outline of Key players/manufacturers:

Get a Sample Copy of the Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market Report 2020

Short Description about Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market:

The report also focuses on global major leading industry players of Global Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies market providing information such as company profiles, product picture and specification, capacity, production, price, cost, revenue and contact information. This report focuses on Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market Trend, volume and value at global level, regional level and company level. From a global perspective, this report represents overall Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market Size by analyzing historical data and future prospect.

The global Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market is anticipated to rise at a considerable rate during the forecast period, between 2020 and 2026. In 2020, the market was growing at a steady rate and with the rising adoption of strategies by key players, the market is expected to rise over the projected horizon.

The Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies market is expected to grow at a Highest CAGR during the forecast period 2020-2026.

On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into

On the basis of the end users/applications, this report focuses on the status and outlook for major applications/end users, consumption (sales), market share and growth rate for each application, including

Enquire before purchasing this report https://www.researchreportsworld.com/enquiry/pre-order-enquiry/15618454

Geographically, this report is segmented into several key regions, with sales, revenue, market share and growth Rate of Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies in these regions, from 2020 to 2026, covering

This Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market Research/Analysis Report Contains Answers to your following Questions

Purchase this report (Price 3900 USD for single user license) https://www.researchreportsworld.com/purchase/15618454

Major Points from Table of Contents:

1 Report Overview 1.1 Study Scope 1.2 Key Market Segments 1.3 Players Covered: Ranking by Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Revenue 1.4 Market Analysis by Type 1.4.1 Global Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market Size Growth Rate by Type: 2020 VS 2026 1.4.2 Platelet Rich Plasma Injections 1.4.3 Stem Cell Therapy 1.5 Market by Application 1.5.1 Global Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market Share by Application: 2020 VS 2026 1.5.2 Dermatology Clinics 1.5.3 Hospitals 1.6 Coronavirus Disease 2019 (Covid-19): Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Industry Impact 1.6.1 How the Covid-19 is Affecting the Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Industry 1.6.1.1 Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Business Impact Assessment Covid-19 1.6.1.2 Supply Chain Challenges 1.6.1.3 COVID-19s Impact On Crude Oil and Refined Products 1.6.2 Market Trends and Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Potential Opportunities in the COVID-19 Landscape 1.6.3 Measures / Proposal against Covid-19 1.6.3.1 Government Measures to Combat Covid-19 Impact 1.6.3.2 Proposal for Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Players to Combat Covid-19 Impact 1.7 Study Objectives 1.8 Years Considered

2 Global Growth Trends by Regions 2.1 Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market Perspective (2015-2026) 2.2 Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Growth Trends by Regions 2.2.1 Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market Size by Regions: 2015 VS 2020 VS 2026 2.2.2 Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Historic Market Share by Regions (2015-2020) 2.2.3 Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Forecasted Market Size by Regions (2021-2026) 2.3 Industry Trends and Growth Strategy 2.3.1 Market Top Trends 2.3.2 Market Drivers 2.3.3 Market Challenges 2.3.4 Porters Five Forces Analysis 2.3.5 Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market Growth Strategy 2.3.6 Primary Interviews with Key Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Players (Opinion Leaders)

3 Competition Landscape by Key Players 3.1 Global Top Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Players by Market Size 3.1.1 Global Top Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Players by Revenue (2015-2020) 3.1.2 Global Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Revenue Market Share by Players (2015-2020) 3.1.3 Global Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market Share by Company Type (Tier 1, Tier 2 and Tier 3) 3.2 Global Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market Concentration Ratio 3.2.1 Global Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market Concentration Ratio (CR5 and HHI) 3.2.2 Global Top 10 and Top 5 Companies by Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Revenue in 2019 3.3 Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Key Players Head office and Area Served 3.4 Key Players Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Product Solution and Service 3.5 Date of Enter into Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market 3.6 Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type (2015-2026) 4.1 Global Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Historic Market Size by Type (2015-2020) 4.2 Global Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Forecasted Market Size by Type (2021-2026)

5 Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Breakdown Data by Application (2015-2026) 5.1 Global Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market Size by Application (2015-2020) 5.2 Global Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Forecasted Market Size by Application (2021-2026)

6 North America 6.1 North America Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market Size (2015-2020) 6.2 Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Key Players in North America (2019-2020) 6.3 North America Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market Size by Type (2015-2020) 6.4 North America Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market Size by Application (2015-2020)

7 Europe 7.1 Europe Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market Size (2015-2020) 7.2 Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Key Players in Europe (2019-2020) 7.3 Europe Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market Size by Type (2015-2020) 7.4 Europe Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market Size by Application (2015-2020)

8 China 8.1 China Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market Size (2015-2020) 8.2 Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Key Players in China (2019-2020) 8.3 China Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market Size by Type (2015-2020) 8.4 China Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market Size by Application (2015-2020)

9 Japan 9.1 Japan Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market Size (2015-2020) 9.2 Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Key Players in Japan (2019-2020) 9.3 Japan Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market Size by Type (2015-2020) 9.4 Japan Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market Size by Application (2015-2020)

10 Southeast Asia 10.1 Southeast Asia Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market Size (2015-2020) 10.2 Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Key Players in Southeast Asia (2019-2020) 10.3 Southeast Asia Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market Size by Type (2015-2020) 10.4 Southeast Asia Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market Size by Application (2015-2020)

11 India 11.1 India Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market Size (2015-2020) 11.2 Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Key Players in India (2019-2020) 11.3 India Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market Size by Type (2015-2020) 11.4 India Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market Size by Application (2015-2020)

12 Central & South America 12.1 Central & South America Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market Size (2015-2020) 12.2 Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Key Players in Central & South America (2019-2020) 12.3 Central & South America Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market Size by Type (2015-2020) 12.4 Central & South America Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market Size by Application (2015-2020)

13 Key Players Profiles 13.1 Orange County Hair Restoration Center 13.1.1 Orange County Hair Restoration Center Company Details 13.1.2 Orange County Hair Restoration Center Business Overview and Its Total Revenue 13.1.3 Orange County Hair Restoration Center Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Introduction 13.1.4 Orange County Hair Restoration Center Revenue in Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Business (2015-2020)) 13.1.5 Orange County Hair Restoration Center Recent Development 13.2 Hair Sciences Center of Colorado 13.2.1 Hair Sciences Center of Colorado Company Details 13.2.2 Hair Sciences Center of Colorado Business Overview and Its Total Revenue 13.2.3 Hair Sciences Center of Colorado Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Introduction 13.2.4 Hair Sciences Center of Colorado Revenue in Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Business (2015-2020) 13.2.5 Hair Sciences Center of Colorado Recent Development 13.3 Anderson Center for Hair 13.3.1 Anderson Center for Hair Company Details 13.3.2 Anderson Center for Hair Business Overview and Its Total Revenue 13.3.3 Anderson Center for Hair Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Introduction 13.3.4 Anderson Center for Hair Revenue in Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Business (2015-2020) 13.3.5 Anderson Center for Hair Recent Development 13.4 Evolution Hair Loss Institute 13.4.1 Evolution Hair Loss Institute Company Details 13.4.2 Evolution Hair Loss Institute Business Overview and Its Total Revenue 13.4.3 Evolution Hair Loss Institute Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Introduction 13.4.4 Evolution Hair Loss Institute Revenue in Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Business (2015-2020) 13.4.5 Evolution Hair Loss Institute Recent Development 13.5 Savola Aesthetic Dermatology Center 13.5.1 Savola Aesthetic Dermatology Center Company Details 13.5.2 Savola Aesthetic Dermatology Center Business Overview and Its Total Revenue 13.5.3 Savola Aesthetic Dermatology Center Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Introduction 13.5.4 Savola Aesthetic Dermatology Center Revenue in Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Business (2015-2020) 13.5.5 Savola Aesthetic Dermatology Center Recent Development 13.6 Virginia Surgical Center 13.6.1 Virginia Surgical Center Company Details 13.6.2 Virginia Surgical Center Business Overview and Its Total Revenue 13.6.3 Virginia Surgical Center Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Introduction 13.6.4 Virginia Surgical Center Revenue in Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Business (2015-2020) 13.6.5 Virginia Surgical Center Recent Development 13.7 Hair Transplant Institute of Miami 13.7.1 Hair Transplant Institute of Miami Company Details 13.7.2 Hair Transplant Institute of Miami Business Overview and Its Total Revenue 13.7.3 Hair Transplant Institute of Miami Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Introduction 13.7.4 Hair Transplant Institute of Miami Revenue in Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Business (2015-2020) 13.7.5 Hair Transplant Institute of Miami Recent Development 13.8 Colorado Surgical Center & Hair Institute 13.8.1 Colorado Surgical Center & Hair Institute Company Details 13.8.2 Colorado Surgical Center & Hair Institute Business Overview and Its Total Revenue 13.8.3 Colorado Surgical Center & Hair Institute Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Introduction 13.8.4 Colorado Surgical Center & Hair Institute Revenue in Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Business (2015-2020) 13.8.5 Colorado Surgical Center & Hair Institute Recent Development

14 Analysts Viewpoints/Conclusions

15 Appendix 15.1 Research Methodology 15.1.1 Methodology/Research Approach 15.1.2 Data Source 15.2 Disclaimer 15.3 Author Details

Continued..

Browse complete table of contents at

https://www.researchreportsworld.com/TOC/15618454

About Us:

Research Reports World is the credible source for gaining the market reports that will provide you with the lead your business needs. At Research Reports World, our objective is providing a platform for many top-notch market research firms worldwide to publish their research reports, as well as helping the decision makers in finding most suitable market research solutions under one roof. Our aim is to provide the best solution that matches the exact customer requirements. This drives us to provide you with custom or syndicated research reports.

CONTACT US

Name: Ajay More

Email:[emailprotected]

Phone:US +1 424 253 0807 /UK +44 203 239 8187

Other Reports Here:

Diphenhydramine Market Research Reports 2020 Global COVID-19 Impact on Industry Size, Share, In-Depth Qualitative Insights, Explosive Growth Opportunity, Regional Analysis by Research Reports World

Global Quasi Continuous Wave (QCW) Lasers Market impact of COVID-19 on Share, Size 2020 Movements by Growth Status, Trend Analysis, Revenue Expectation to 2025 Research Report by Research Reports World

Portable Speakers Market 2020 Covid-19 Impact Analysis on Global Industry Size, Recent Trends, Demand and Share Estimation by 2026 with Top Players ResearchReportsWorld.com

Rehab Equipment Market Covid-19 Impact on Size, share 2020 Global Industry Trends, Growth Drivers, Demands, Business Opportunities and Demand Forecast to 2024

Pocket Filter (ISO16890) Market Size, Share, 2020 Global COVID-19 Impact on Industry Growth, Trends, Emerging Factors, Demands, Key Players, Emerging Technologies and Potential of Industry Till 2025

Emergency Shower & Eye Wash Station Market Share, Size 2020 Global impact of COVID-19 on Industry Forecasts Growth, Analysis, Company Profiles, Competitive Landscape and Key Regions Analysis Available at Research Reports World

Read the original post:
Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market 2020 COVID-19 Impact on Industry Size, Share, Company Profiles, Emerging...

Platelet-Rich Plasma (PRP) Specialist – Farmington, NM …

What is PRP?

Platelet-rich plasma (PRP) is a regenerative medicine treatment that uses components of your own blood. Plasma is the liquid base of your blood that contains solid substances, including red cells, white cells, and platelets.

In addition to clotting blood, platelets contain proteins called growth factors that stimulate your bodys healing process. PRP has about 5-10 times more platelets than regular blood. When injected into an area of damaged tissue, PRP releases a flood of growth factors that promote healing.

Scientists are currently researching the effectiveness of PRP on various diseases and injuries. Existing research shows that PRP injections are more effective than other treatments, such as viscosupplementation, at reducing pain and symptoms in patients with osteoarthritis of the knee.

In addition to arthritis, the team at Orthopedic Associates PA may use PRP to speed up the healing process for a variety of conditions, including:

They use PRP therapy on many parts of the body, including the foot and ankle, knee, hip, shoulder, elbow, hand, and wrist.

While more research is needed to understand exactly how PRP works, clinical studies suggest that it provides several benefits in orthopedic applications, including:

PRP treatment can improve your quality of life and functional mobility while reducing the need for surgery and pain-relieving medications.

PRP therapy is an in-office treatment that doesnt require surgery, anesthesia, or risk of serious side effects. First, your provider at Orthopedic Associates PA draws a vial of blood, typically from your arm. They process the blood to obtain PRP.

Then, they inject the PRP into the area of injured or damaged tissue. The growth factors trigger a cascade of healing and tissue regeneration in the treatment area. Because inflammation is a natural part of this process, its normal to experience a temporary increase in swelling and pain for a few days.

To learn how PRP therapy can improve your quality of life, call Orthopedic Associates PA, or book an appointment online today.

Read more here:
Platelet-Rich Plasma (PRP) Specialist - Farmington, NM ...

A & # 39; s slam Angels in the first MLB game with a new additional entry rule – NewsDio

The first major league game with a runner on additional innings was decided with a bang rather than a tap.

Marcus Semien started the end of the tenth at second base under the unpopular new rule and scored on Matt Olson's grand slam, sending the Oakland Athletics over the Los Angeles Angels 7-3 on Friday night.

GIANT PITCHER SAM COONROD REFUSES TO KNEE DURING THE TIME OF BLACK LIVES BY FAITH: "I AM A CHRISTIAN"

Olson, whose alert pitch from first base nailed Angels free agent Shohei Ohtani to the top of the tenth, hooked up with one out. The Athletics gathered around the plate to greet him on opening night.

It is definitely interesting. There will be more excitement, "Olson said." I think it would be much harder to go to 17 or 18 inning games with a guy in second place. You would think that sometime someone will probably get hit.

Major League Baseball instituted the controversial extra inning runner rule for this season to prevent games from dragging on amid a compressed 60-game schedule that began after a months delay due to the virus outbreak.

Ohtani, who had put an end to the Angels ninth, was not ready for that: the broadcast showed the Japanese star on the bench wearing a jersey when the game was extra. Surprised, someone reminded him that he had to go to the second and quickly got organized.

Ohtani tried to advance Jared Walsh's initial landing, but was tagged in a summary.

TAMPA BAY LIGHTNING CALLS TO DETECT OFFICERS INVOLVED IN BREONNA TAYLOR'S DEATH OF SHOOTING

"I feel like we're going to see some different things with that," Olson said.

After Semien took second place, the Athletics loaded the bases against Hansel Robles (0-1) in a shot for a pitch, a wild pitch and a walk.

"Let's see what we do," former A-pitcher Dave Stewart wrote on Twitter, and then complained, "I suppose hitting is not an option?"

Then: "We don't need any stinky touches."

Angels new manager Joe Maddon brought in reliever Hoby Milner and, with a five-man inside box in place, Olson hit the first pitch well above the wall in right field.

According to STATS, Olson became the third player to reach a starting Grand Slam on opening day. He joined Sixto Lezcano (1980 Brewers) and Jim Presley (1986, Marineros).

Burch Smith (1-0) pitched an inning for victory.

The game went to the tenth tied at 3 after Jason Castro's home run in the ninth against A closer Liam Hendriks.

The Angels did not achieve a victory for Maddon in his debut as manager of the Angels. Maddon joined the Angels after five seasons guiding the Chicago Cubs.

CLICK HERE FOR MORE SPORTS COVERAGE AT FOXNEWS.COM

"We're basically playing a third of a season, so it's like losing a three-game series." That's what it feels like, "Angels starter Andrew Heaney said.

Many of the Angels, including Justin Upton and Brian Goodwin, knelt for the national anthem, while Athletics players Khris Davis and Tony Kemp raised their right fists to the air.

Los Angeles opened the season in Oakland for the fourth consecutive year.

TWO DECADES

At age 40, Albert Pujols had his 20th consecutive start on Opening Day in the same number of years the fifth player to start the opening in 20 consecutive years. The Others: Pete Rose, Carl Yastrzemski, Eddie Murray, and Frank Robinson.

It was 0 for 3 with a walk.

"Pretty spectacular, isn't it?" Maddon said. That puts everything in perspective of how great he is, how his career has looked, just to have 20 chances, you have to be good. We've had a lot of great conversations lately, me and him. Very happy for him and his family. I know it is important to him. He's definitely ready for rock and roll. "

COACH ROOM

Angeles: New 3B Anthony Rendon missed the first game with an oblique injury. "It has progressed, it encourages me," Maddon said.

Athletics: LHP A.J. Puk, on the disabled list with a tense shoulder, played catch. General manager David Forst said Puk would go to the club's alternate site in San Jose when the club hits the road. Puk received injections of platelet-rich plasma and cortisone on Monday. "It's going to be at least a couple of weeks just playing catch," manager Bob Melvin said. "We are a long way from having an update on him."

THAT FEAT

David Rinetti, A's vice president of stadium operations, marked his 40th inaugural day with the organization after first working in 1981 as a high school student. He received a 113-page document to prepare the stadium in two weeks.

"It's pretty incredible. It was a lot of work," said Rinetti.

UNTIL NEXT TIME

LHP Sean Manaea, who was 4-0 last season in September after returning from shoulder surgery before losing the wild card game, pitches Saturday against the Angels RHP Dylan Bundy.

Originally posted here:
A & # 39; s slam Angels in the first MLB game with a new additional entry rule - NewsDio

Platelet-Rich Plasma |Therapy (PRP) Everything You Need to …

Soft tissue injury has become one of the major reasons for clinic visits in the United States. It has been estimated that more than a million clinic consultations per year are because of soft tissue injury. (1) In the 33 million musculoskeletal injuries per year, 50% often include tendon and ligament injuries (2), while anterior cruciate ligament (ACL) rupture counts to 100,000 to 200,000 per year. (3)

In the 1970s, when a lot of medical discovery was happening, was also the time when platelet-rich plasma therapy was discovered and applied in regenerative medicine (4).

So, what is platelet-rich plasma and why is it for you? In this article, we will be discussing comprehensively on what it really is and why this could be the golden treatment of the century.

Platelet-rich plasma has been around for quite some time. It has been experimented and studied in thousands of clinical trials and with publications in hundreds of medically renowned journals. It has been used in different areas of medicine such as dentistry, plastic and cosmetic surgery, trauma, maxillofacial surgery, and even veterinary medicine.

In the 1970s, hematologists first started the concept of platelet-rich plasma. They created the term to describe plasma with platelet count that surpassed the number of that from peripheral blood, which was used for patients with thrombocytopenia or low platelet count. (5)

It was first used in maxillofacial surgery to help stimulate cells, and eventually, it has gained a lot of attention because of its use in sports injury such as ligament injuries, muscle strains, cartilage injury, and even on early osteoarthritis.

Apart from the interest of platelet-rich plasma, it is currently gaining a lot of noise because of its application in dermatology. It is also being used to help rejuvenate the skin, treat alopecia or hair loss, and even in wound healing and scar revision.

Now that you have read a little on platelet-rich plasma, lets deconstruct them one by one. So what is plasma? Youve heard it before but what is it really and why is it relevant as a treatment to a lot of injuries? Plasma or blood plasma is the light- yellow to straw yellow liquid found in our blood. When we say whole blood this includes the red blood cells, the white blood cells, and the platelets.

Plasma is about 91 to 92% water and only 8 to 9% solid material. It contains fibrinogen, an important factor in clotting blood. It also has proteins like albumin and globulin that help maintain the balance in the blood. Sodium, potassium, bicarbonate, chloride, and calcium are also present in the plasma to help maintain the normal value of blood pH. Lastly, it also contains immunoglobulins that protect our body from both viral and bacterial infections. (6)

Plasma can be extracted and separated by centrifugation which we will tackle later on. 55% of our blood is plasma and it is formed from the water and salt that has been absorbed by our stomach and intestines. The bone marrow, dead blood cells, and the other tissues of the body also help in the formation of plasma. Our plasma can also be used as a laboratory test. It can help diagnose diseases like diabetes and can help detect levels of albumin in the body.

Plasma is amazing because it is used in a lot of ways. Fresh frozen plasma helps in the treatment of people who have massive bleeding that results in shock like seen in burns or those with trauma. It can also help in clotting especially in those suffering from massive internal bleeding or for people with clotting abnormalities.

To understand platelet-rich plasma therapies, we must know the star of the show first, the platelet! You have heard it before in 3rd grade but have you ever wondered why platelets are such important factors and why it has become one of the most studied cells of the body?

Platelets are very small but despite the size, they have a lot of purpose in our bodies. The normal platelet count is from 150,000 to 400,000 platelets per microliter. They are formed from very large cells that break off to eventually become platelets. The lifespan of platelets is at 7-10 days on average and then they are removed from the bloodstream. (7)

They have a lot of functions in the body. They help you clot by sticking together and starting the coagulation cascade where a mesh-like structure is made to prevent the leaking of more blood products when there is a break in the skin or even when there is injury in our internal organs.

Platelets are the first cells to arrive when there is injury and are active in the early part of the inflammation stage of the body. In simple words, they are important in maintaining balance to our body when problems arise. They also store antibacterial and even fungicidal proteins which help in activating other processes in the body that deals with inflammation. This is where the healing property of platelets lies they help deal with the pain because they help with the inflammation and they facilitate the recovery of the body through the growth factors that are associated with healing.

Now, the part that I am excited to talk about what is platelet-rich plasma and why all the fuss?

Platelet-rich plasma is an efficient and minimally invasive (meaning theres almost no pain and it is a very fast procedure!) method that is done by getting your own blood and separating the red blood cells from the plasma through the process, centrifuging. I promised to discuss centrifuging earlier and here it is: Centrifuging is done using a machine that slowly swirls the blood around to separate the plasma, which contains platelets. This process is very fast and can take up to 10 minutes only.

The attraction of using platelet-rich plasma is in its ability to deliver growth factors and other cytokines that contain functions that can optimize healing in sites of injury like those commonly seen in sports. Growth factors are important because they can give the body the boost needed to heal at a faster than usual rate. It is also very appealing because it has a very low cost, minimally invasive, safe, and easy to do.

Getting into the technicality of PRP, there are a lot of commercially available devices that can produce PRP and various techniques have been developed but the end goal remains the same: faster recovery, improvement of pain, and getting the body back to normal after an injury.

Platelet-rich plasma is just as the name suggests millions of platelets in the plasma, extracted from the patient himself or through commercially-prepared PRPs, thus making it 100% safe from any allergic reaction or infection, given to areas in the body with injuries or problems.

Since it has been around for more than 50 years, platelet-rich plasma has been used in medicine countless of ways:

The use of platelet-rich plasma in tendinopathies has been done in several well-known studies. The cytokines and growth factors found in PRP are involved in helping regrow tissues, faster healing, and decreasing inflammation. PRP may also help in increasing the blood supply of the damaged tendons, by giving abundant nutrients to the area to help cells regenerate faster and bringing new cells that can remove the damaged tissues.

PRP has been a known method of treatment for several orthopedic injuries like lateral epicondylitis, patellar tendinopathy, Achilles tendinopathy, rotator cuff tendinopathy, and plantar fasciitis. It helps as a treatment for patients who do not respond to physical therapy. In one study done by Mishra et al., they evaluated 230 patients who did not respond to conservative treatment and used PRP and it showed that there was a significant improvement to their pain compared to that of the control group. (8)

There are even more studies that have noted improvement for patients undergoing PRP especially those who have received leukocyte rich PRP because of its pro-inflammatory effects. Patients who belonged in studies that had PRP treatment reported better activity, improved pain and function compared to those who belonged in the placebo group. This is important especially if you are a patient looking for a way to improve your pain and at the same time gain back your function.

Platelet-rich plasma has now been incorporated in some surgeries especially those involving the bones and the tendons. A lot of the studies are looking into incorporating PRP into the preparation that will help improve the strength and functional outcomes of patients. PRP has been used in surgeries for rotator cuff repair, Achilles tendon repair, and anterior cruciate ligament surgery. Promising results are now being reported by new clinical trials involving PRP and its uses in surgery. (9)

The use of platelet-rich plasma for osteoarthritis has long been studied. Osteoarthritis is the most common form of arthritis and presents with joint pain and loss of function. It is very variable and can present in several ways but it is a devastating disease that can leave the patient to become disabled.

Platelet-rich plasma is used in osteoarthritis involving the knee and hip. If you have had osteoarthritis, you would know how upsetting it is to realize that your bones will never be the same and the constant pain that it can give. Researchers have found out that intra-articular PRP has become very effective in osteoarthritis and helps decrease pain and inflammation of the areas involved. (9)

This is explained by the different anti-inflammatory mediators found in platelets (such as TNF-, IL-6, and IL-1) which all help in blocking the activities of factors that may cause inflammation within the bones and cartilages.

Apart from bones and tendons, PRP is believed to have shown improvement in muscle healing also because of the inflammatory response and improvement in cell movement and growth.

PRP is well-known nowadays in the world of dermatology. This is because of its ability to improve skin structure by rejuvenating the skin and making the cells newer while basically throwing away the old or dead cells. It can also significantly reduce scars especially newer ones. Surprisingly, one well-known use of PRP is for hair loss. Because of the growth factors released by PRP, it is believed to help in the proliferation of the cell, which is essential in new hair regrowth. (10)

As mentioned earlier, platelet-rich plasma is done in the office. A few tubes of your blood is extracted, and run on a centrifuge machine for 10 minutes. Once the platelet-rich plasma has been separated from the red blood cells, it will be extracted. We will then slowly inject the platelet-rich plasma that we have taken using very thin needles into the areas where you feel pain. Once these are injected, you may feel improvements in your pain already!

The procedure itself will take less than an hour if done in a single area like the knee or elbow. You will feel little to no pain during the procedure and it will be done by our expert physicians in PremierMed.

You may need repetitive injections of PRP if you have been having chronic pain or when the damage has been present for a long time. Platelet-rich plasma therapy may take weeks or months but the effect and healing that it can provide are long-lasting and life-changing.

As discussed, PRP has become one of the emerging treatments for pain, especially of the tendons and bones. This is important especially when your injury is not only giving you pain but limiting you from doing all the things you love!

To recap our discussion of platelet-rich plasma therapy here is what we covered:

Pain and injury should not be part of your daily life. We now live in a world where anything and everything can be improved. If you think PRP is for you, you can visit us for more details or book an appointment to live the life that you have been missing out on!

References:

Go here to read the rest:
Platelet-Rich Plasma |Therapy (PRP) Everything You Need to ...

Takeaways from the As loss to the Giants: Why is the offense cold? Who is the Opening Day second baseman? – Chico Enterprise-Record

The Oakland As traveled across the Bay Bridge to play the second of a two-game exhibition series against the San Francisco Giants, losing 4-2.

This short and semi-sweet summer is over, and the As are clearly shaking off some rust heading into Opening Day at home against the Los Angeles Angels at the Oakland Coliseum.

Here are some takeaways from the last exhibition game of 2020.

As offense goes cold

The As scored all of four runs in these two losses. Stephen Piscotty hit a home run on Monday, and Chad Pinder hit a two-run double off the deep centerfield bricks at Oracle Park on Tuesday that the naked eye tells us was actually a home run.

Manager Bob Melvin challenged it, and the base hit call was upheld with very little explanation.

That the As faced 18 different pitchers in 18 innings probably didnt help ignite the offensive momentum. But, rare high points and a handful of competitive at bats aside, the As put together some rough plate appearances in these exhibition games.

We would have like to have better offense here the last couple games, just didnt happen, manager Bob Melvin said. We have a good offensive team, so its not concerning. Just didnt do a whole lot.

The As struck out eight times on Monday, 12 times on Tuesday. Through these two games, theyve collected six hits and eight walks.

If the As want to avoid a slow star thats plagued them in recent years, the sluggish offense theyve displayed certainly isnt promising.

Whos on second?

For all the hullabaloo surrounding second base during Spring Training 1.0 will it be Jorge Mateo? Tony Kemp? Franklin Barreto? Vimael Machin? Will there be a platoon? Will one player play the lions share? theres a chance Pinder could be the starting second baseman against Angels left-handed starter Andrew Heaney, Melvin said.

If not at second, expect Pinder somewhere in the lineup.

Pinder has been a standout at the plate during this camp, and hes had success against left-handed pitching: slashing .252/.313/.436 with a .748 OPS and 112 wRC+ against them.

If Pinder starts at second base, what does this mean for Barreto? He had one at bat in Tuesdays game, resulting in a strikeout. None on Monday.

Barreto also caught the teams attention at camp, where he hit two quick home runs off Frankie Montas and Liam Hendriks. Coaches have said that Barreto is in need of consistent at bats to show that his high ceiling he demonstrated in the minor leagues power at the plate, speed on the bases can translate to the big leagues.

Having too much talent at one position is a good problem to have. But, somehow the second base picture got a little more fuzzy. Maybe thats OK.

Fiers got the start at Oracle Park on Tuesday, allowing two home runs to Mike Yastrzemski to lead off the first inning and Alex Dickerson in the second inning on 67 pitches in 3.1 innings. He walked Pablo Sandoval before his exit in the fourth, and Sandoval scored on a sac fly off of Joakim Soria for Fiers third earned run.

The right-handed pitchers command was a tad off and he fumbled a few signs with catcher Austin Allen.

Allen, who was named to the 30-man roster as the backup catcher, is still adjusting to Fiers unpredictability and backwards pitching style.

I made it tough on myself, Fiers said after his start. I was just wild. Wasnt throwing the ball exactly where I wanted to. Just a little erratic.

Got another five days before games actually start, for me at least.

Fiers first meaningful start should come on Sunday, where hell go head-to-head with Angels phenom Shohei Ohtani. Fiers missed the first few days of camp taking extra precautions due to exposure to Jess Luzardo, who tested positive for the coronavirus prior to report day.

Because Fiers threw bullpens during the hiatus, he wasnt too far behind his fellow rotation mates. Even if this start left a sour taste in his mouth, Fiers curveball looked season ready.

Remember, Fiers curveball had one of the best vertical drops in baseball in 2019. His 70.7 vertical drop is 7.7 inches over the league average which ranks eighth in all of baseball.

Chris Bassitt looks ready to roll

Bassitt was a step behind the rest of the starters heading into camp. He hadnt faced live hitting during the hiatus like the others had.

He caught up quickly, and looked rotation ready dealing four innings with five strikeouts in Tuesdays game. His fastball hit 95 mph and he had command of his changeup and curveball.

Hell pitch fourth out of the rotation, on Monday against the Angels.

A.J. Puk and Jess Luzardo update

Puk traveled to Los Angeles to meet with Dr. Neal ElAttrache on Monday and received platelet-rich plasma and cortisone injections in his strained left shoulder, As manager Bob Melvin said Tuesday.

Puk is likely to be sidelined for two weeks, at least, and is resting for the next 48 hours.

The left-handed pitcher was slotted to start the season in the fifth spot of Oaklands rotation, but was placed on the 10-day IL. Right-handed pitcher Daniel Mengden will fill in for him in the rotation until Puks return from injury.

Jess Luzardo is slated to pitch in either the first or second game of the regular season, Melvin announced. Luzardo, who missed the first two weeks of camp after testing positive for coronavirus, is expected to come out of the bullpen and build his arm up to pitching three innings until he can be slotted into the rotation.

Luzardo pitched to Ramn Laureano in live batting practice prior to Mondays game against the San Francisco Giants.

Other notes

See the article here:
Takeaways from the As loss to the Giants: Why is the offense cold? Who is the Opening Day second baseman? - Chico Enterprise-Record